Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24433940 | 0.90 | NAAA (0.38) | SLC6A4SLC6A3NAAAKDM4EGRM5 | |
| SCHEMBL4084625 | 0.82 | CNR2 (0.47) | NAAAKDM4EEPHX2TSHRALDH1A1 | |
| SCHEMBL23912852 | 0.80 | OPRM1 (0.37) | EPHX2FAAH | |
| SCHEMBL24433911 | 0.79 | FAAH (0.34) | SLC6A4SLC6A3FAAH | |
| SCHEMBL24433939 | 0.78 | FAAH (0.39) | FAAH | |
| SCHEMBL24454992 | 0.78 | CNR2 (0.40) | SLC6A4SLC6A3NAAAKDM4EEPHX2 | |
| SCHEMBL4078545 | 0.75 | NAAA (0.43) | SLC6A4SLC6A3NAAAKDM4EGRM5 | |
| SCHEMBL4078442 | 0.73 | NAAA (0.46) | SLC6A4SLC6A3NAAAKDM4EGRM5 | |
| SCHEMBL4075740 | 0.73 | KMT2A (0.45) | NAAAPOLB | |
| SCHEMBL4080289 | 0.73 | NAAA (0.43) | SLC6A4SLC6A3NAAAKDM4EGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | CNR1, CNR2, FAAH | SLC6A4 485/4885SLC6A3 1279/4885NAAA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.